| Risk | Moderately High |
|---|---|
| Min SIP Amount | Not Supported |
| Expense Ratio | 0.00% |
| NAV | ₹11.39 (27 Oct 2020) |
|---|---|
| Fund Started | 12 Feb 2018 |
| Fund Size | ₹327 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Infosys Ltd. | Technology | Equity | 9.4% |
| Ipca Laboratories Ltd. | Healthcare | Equity | 7.6% |
| ICICI Bank Ltd. | Financial | Equity | 7.0% |
| Multi Commodity Exchange India | Financial | Equity | 6.8% |
| Cipla Ltd. | Healthcare | Equity | 6.2% |
| Torrent Pharmaceuticals Ltd. | Healthcare | Equity | 5.8% |
| Crompton Greaves Consumer Electricals Ltd. | Cons Durable | Equity | 5.7% |
| Gujarat Gas Ltd. | Chemicals | Equity | 5.3% |
| Eicher Motors Ltd. | Automobile | Equity | 4.9% |
| Axis Bank Ltd. | Financial | Equity | 3.8% |
UTI Focussed Equity Fund Series VI (1150 Days) Direct Growth is a Equity Mutual Fund Scheme launched by Axis Mutual Fund. This scheme was made available to investors on 12 Feb 2018. Vetri Subramaniam, Sachin Trivedi is the Current Fund Manager of UTI Focussed Equity Fund Series VI (1150 Days) Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹327 Cr and the Latest NAV as of 27 Oct 2020 is ₹11.39.
The UTI Focussed Equity Fund Series VI (1150 Days) Direct Growth is rated Moderately High risk.
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of listed companies. The scheme will without any capitalization bias endeavour to invest in either growth stocks or value stocks or both. The Scheme will normally hold upto 30 stocks in the portfolio.